Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Fluciclovine PET for Brain Metastasis Treated With SRS
NCT06048094Phase 1Recruiting
- Sponsor
- Baptist Health South Florida
- Start
- Apr 2024
- Primary completion
- Jun 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluciclovine f 18 in brain metastasis (BM), sponsored by Baptist Health South Florida. Primary endpoints: Change in Standardized Uptake Value (SUV)-peak at 8 weeks, Change in Standardized Uptake Value (SUV) mean at 8 weeks and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
fluciclovine f 18
03
Conditions
brain metastasis (BM)
Beyond the preview
Go deeper on NCT06048094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048094.